Tisdag 3 November | 11:53:24 Europe / Stockholm
Est. tid*
2027-02-09 07:00 Bokslutskommuniké 2026
2026-11-03 07:00 Kvartalsrapport 2026-Q3
2026-08-18 - Kvartalsrapport 2026-Q2
2026-06-10 - X-dag ordinarie utdelning OSSD 0.00 SEK
2026-06-09 - Årsstämma
2026-05-05 - Kvartalsrapport 2026-Q1
2026-02-03 - Bokslutskommuniké 2025
2025-11-04 - Kvartalsrapport 2025-Q3
2025-08-19 - Kvartalsrapport 2025-Q2
2025-06-12 - X-dag ordinarie utdelning OSSD 0.00 SEK
2025-06-11 - Årsstämma
2025-05-06 - Kvartalsrapport 2025-Q1
2025-02-04 - Bokslutskommuniké 2024
2024-12-18 - Extra Bolagsstämma 2024
2024-11-12 - Kvartalsrapport 2024-Q3
2024-08-20 - Kvartalsrapport 2024-Q2
2024-05-22 - X-dag ordinarie utdelning OSSD 0.00 SEK
2024-05-21 - Årsstämma
2024-05-14 - Kvartalsrapport 2024-Q1
2024-02-06 - Bokslutskommuniké 2023
2023-11-21 - Kvartalsrapport 2023-Q3
2023-10-16 - Extra Bolagsstämma 2023
2023-08-22 - Kvartalsrapport 2023-Q2
2023-06-01 - X-dag ordinarie utdelning OSSD 0.00 SEK
2023-05-31 - Årsstämma
2023-05-23 - Kvartalsrapport 2023-Q1
2023-02-21 - Bokslutskommuniké 2022
2022-11-22 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning OSSD 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-02-22 - Bokslutskommuniké 2021
2021-11-17 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-20 - X-dag ordinarie utdelning OSSD 0.00 SEK
2021-05-19 - Årsstämma
2021-05-12 - Kvartalsrapport 2021-Q1
2021-04-09 - Extra Bolagsstämma 2021
2021-02-11 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
2020-08-19 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning OSSD 0.00 SEK
2020-05-20 - Årsstämma
2020-05-13 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-19 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
OssDsign är en utvecklare och leverantör av ortobiologiska produkter. Bolaget utvecklar och marknadsför produkter som stödjer kroppens egen läkningsförmåga, exempelvis OssDsign Catalyst, som är ett nanosyntetiskt bentransplantat för dubbla benbildningsvägar genom fusionsmassa. Bolaget erbjuder sina produkter runtom den globala marknaden. OssDsign grundades år 2011 och har sitt huvudkontor i Uppsala.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

OssDsign AB (publ) publishes Q3 2026 interim report

2026-11-03 07:00:00

Focused on the levers for sales growth

OssDsign AB (publ) announces that the interim report for Q3 2026 is now available as a PDF on the company's website www.ossdsign.com/reports. A PDF version is also attached to this press release.

 

The Q3 2026 results will also be presented at an investor webcast today November 3rd at 11:00 CEST. The webcast can be accessed via the following link: https://access.dnbcarnegie.com/companies/1392/live or via the OssDsign website.  

 

 

The third quarter in figures

  • Net sales amounted to TSEK 35,728 (44,020), which translates to an 8.2% decrease quarter-over-quarter with constant exchange rates, or 5.4% decrease in reported figures. This was in line with our expectations, as we commented during our Q2 release.
  • Gross margin of 93.2% is an improvement over 92.1% in the previous quarter of 2026 but below 95.6% in the third quarter of the previous year. Some improvement in product and customer mix compared to the previous quarter.
  • Adjusted EBIT of TSEK -6,615 (-5,319), with the reduction in operating expenses compensating for most of the gross profit shortfall.
  • Reported EBIT of TSEK -6,863 (-5,533).
  • Operating expenses were lower than last year with sales variable costs at 49.9% (48.7%) of net sales in the period.
  • Net result for the period amounted to TSEK -5,776 (-5,781).
  • Earnings per share of SEK -0.1 (-0.1).
  • Cash flow from operating activities of TSEK -5,255 (-9,379), better than last year due to the favorable working capital development.

 

The first nine months in figures

  • Net sales amounted to TSEK 110,383 (135,036), which translates to a 13.6% decrease with constant exchange rates, or 18.3% in reported figures.
  • Gross margin of 92.3% (96.3%), negatively affected by product and customer mix.
  • Adjusted EBIT of TSEK -31,979 (-17,086), as a direct consequence of the lower sales and gross margin, with some mitigation from the lower operating expenses.
  • Reported EBIT of TSEK -32,677 (-25,167).
  • Operating expenses were lower than last year and sales variable costs were down to 47.2% (48.9%) of net sales in the period.
  • Net result for the period amounted to TSEK -28,658 (-28,699).
  • Earnings per share of SEK -0.3 (-0.3).
  • Cash flow from operating activities of TSEK -31,932 (-47,148), due to the favorable working capital development in the first nine months of 2026.

  

Significant events during the third quarter

  • OssDsign surpasses 400 patients in PROPEL spine registry evaluating OssDsign Catalyst®.

 

Significant events after the end of the third quarter

  • There were no significant events after the end of the third quarter.

 

 

  

This disclosure contains information that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 03-11-2026 07:00 CET.